MedTrace Logo

An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo

NCT01076439 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-02-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the onset of action of fluticasone furoate nasal spray compared to olopatadine nasal spray and placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after single dose administration and six consecutive days of treatment.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Fluticasone Furoate Nasal Spray

Fluticasone Furoate Nasal Spray: 110mcg QD

DRUG

Olopatadine Nasal Spray

Olopatadine Nasal Spray: 2660mcg BID

DRUG

Saline Nasal Spray

Placebo

Sponsors & Collaborators

  • ORA, Inc.

    lead INDUSTRY

Principal Investigators

  • H. J. Crampton, MD · ORA, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01076439 on ClinicalTrials.gov